PBN.F · Alterity Therapeutics Limited

-

Please sign in to comment on PBN.F

1 Comment

Admin

3 years, 8 months ago

Alterity Therapeutics Limited is currently in a long term downtrend where the price is trading 2.3% below its 200 day moving average.

From a valuation standpoint, the stock is 48.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 673.5.

Alterity Therapeutics Limited's total revenue sank by 0.0% to $928K since the same quarter in the previous year.

Its net income has dropped by 0.0% to $-3M since the same quarter in the previous year.

Finally, its free cash flow fell by 182.8% to $-4M since the same quarter in the previous year.

Based on the above factors, Alterity Therapeutics Limited gets an overall score of 1/5.

Sector	Healthcare
ISIN	AU0000043945
CurrencyCode	EUR
Industry	Biotechnology
Exchange	F

Beta	0.89
Dividend Yield	0.0%
Target Price	None
PE Ratio	None
Market Cap	10M

ABOUT

Alterity Therapeutics Limited

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

PBN.F · Alterity Therapeutics Limited

-

Alterity Therapeutics Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Alterity Therapeutics Limited using a moving average strategy